Produktbild: Atlas of Response to Immunotherapy
- 11%

Atlas of Response to Immunotherapy

11% sparen

106,99 € UVP 120,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

08.12.2020

Herausgeber

Egesta Lopci + weitere

Verlag

Springer

Seitenzahl

127

Maße (L/B/H)

27,9/21/0,8 cm

Gewicht

396 g

Auflage

1st ed. 2020

Sprache

Englisch

ISBN

978-3-030-31115-5

Beschreibung

Rezension

“This publication is one of the first publications in the field ... . In relation to the innovative content, presented and explained by great experts, this atlas is recommended for diagnostic imagers, who already work with hybrid machines, for students of radiology and nuclear medicine, and for all those interested in immunotherapy. This atlas helps in the correct use of innovative therapies in an oncological reality which is already widely used, although not always appropriately.” (Luigi Mansi, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, 2021)

Portrait

Egesta Lopci  was born in Shkoder, Albania. She has graduated cum laude in Medicine and Surgery at the Alma Mater Studiorum, University of Bologna, Italy, and at the same University she finished her specialization in Nuclear Medicine and completed her PhD in Specialized Medical Sciences. In 2017, she obtained the Italian scientific qualification as Professor in Diagnostic Imaging and Radiotherapy.  

As Nuclear Medicine Consultant, she is directly involved in clinical and research activities with particular interest on molecular imaging applications for nuclear oncology. She is an active member of different organizations and research groups, comprising the AIEOP Hodgkin Lymphoma Interest Group, the EANM Oncology Committee, the EORTC Imaging and Lung Cancer Groups, the UEMS/EBNM CME Accreditation Committee, and is Chair of the EORTC IG Educational Subcommittee. Over the years, she has won several grants and over 10 awards and recognitions for herresearch activity. She is author of over 103 scientific papers, 4 books and 11 chapters on Nuclear Medicine discipline, and (co)author of more than 165 congress communications for societies such as EANM, SNMMI, AIMN, ESR, ESMO, ESTRO, EANO, RSNA, AUA, CAYAHL, and IMIG.

Stefano Fanti was born in Bologna, Italy, and studied at the Alma Mater Studiorum, University of Bologna, where he obtained his degree in Medicine and Surgery and later completed his specialization in Nuclear Medicine. Currently he is Associate Professor of Diagnostic Imaging and Director of the Specialty School of Nuclear Medicine at the Alma Mater Studiorum, University of Bologna. He is also Director of the Nuclear Medicine and PET Unit at the University Hospital S. Orsola-Malpighi of Bologna. Dr. Fanti is Chair of the EANM Oncology Committee (2016–2019). He is an associate editor of Clinical and Translational Imaging and an editorial board member for the European Journal of Nuclear Medicine and Molecular Imaging and the Spanish Journal of Nuclear Medicine . He has authored more than 350 articles in peer-reviewed international journals as well as a number of books and book chapters in the field of nuclear medicine.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

08.12.2020

Herausgeber

Verlag

Springer

Seitenzahl

127

Maße (L/B/H)

27,9/21/0,8 cm

Gewicht

396 g

Auflage

1st ed. 2020

Sprache

Englisch

ISBN

978-3-030-31115-5

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

Weitere Artikel finden Sie in

  • Produktbild: Atlas of Response to Immunotherapy
  • PART I BRIEF INTRODUCTION: Immunotherapy in oncology.- Evolution of response criteria.- Part II DIESEASE-ORIENTED APPLICATIONS: CNS.- Thorax.- Melanoma.- Gastrointestinal.- Genitourinary.- Hematologic.- Other tumor types.- PART III PITFALLS AND IMMUNE-RELATED ADVERSE EVENTS (IrAEs) PART IV IMMUNO-PET.